Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Comparison of Real World and Core Laboratory Lupus Anticoagulant Results from the Antiphospholipid Syndrome (APS) ACTION Clinical Database and Repository.

Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, Sciascia S, Krillis S, Bison E, Borges Galhardo Vendramini M, Romay-Penabad Z, Qi M, Tektonidou M, Ugarte A, Chighizola C, Belmont HM, Aguirre MA, Ji L, Branch DW, de Jesus G, Fortin PR, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Ecem S, Bertolaccini ML, Pengo V, Cohen H; APS ACTION.

J Thromb Haemost. 2019 Jul 30. doi: 10.1111/jth.14596. [Epub ahead of print]

PMID:
31364274
2.

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.

Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION.

Semin Arthritis Rheum. 2019 May 2. pii: S0049-0172(19)30090-3. doi: 10.1016/j.semarthrit.2019.04.009. [Epub ahead of print]

PMID:
31153708
3.

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.

Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, Mokrzycki M, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium.

Nat Immunol. 2019 Jul;20(7):915-927. doi: 10.1038/s41590-019-0386-1. Epub 2019 May 20.

PMID:
31110316
4.

3T chemical shift-encoded MRI: Detection of altered proximal femur marrow adipose tissue composition in glucocorticoid users and validation with magnetic resonance spectroscopy.

Martel D, Leporq B, Saxena A, Belmont HM, Turyan G, Honig S, Regatte RR, Chang G.

J Magn Reson Imaging. 2019 Aug;50(2):490-496. doi: 10.1002/jmri.26586. Epub 2018 Dec 12.

PMID:
30548522
5.

Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature review.

Yuriditsky E, Torres J, Izmirly PM, Belmont HM.

Lupus. 2018 Dec;27(14):2269-2273. doi: 10.1177/0961203318804876. Epub 2018 Oct 5. Review.

PMID:
30290716
6.

Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis.

Domingues V, Levinson BA, Bornkamp N, Goldberg JD, Buyon J, Belmont HM.

Lupus Sci Med. 2018 Sep 4;5(1):e000271. doi: 10.1136/lupus-2018-000271. eCollection 2018.

7.

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

de Jesús GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, Pengo V, Ji L, Meroni PL, Ugarte A, Cohen H, Branch DW, Andreoli L, Belmont HM, Fortin PR, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Nascimento IS, Rosa R, Erkan D, Levy RA; APS ACTION.

BJOG. 2019 Apr;126(5):656-661. doi: 10.1111/1471-0528.15469. Epub 2018 Oct 24.

PMID:
30222236
8.

The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County.

Izmirly PM, Buyon JP, Wan I, Belmont HM, Sahl S, Salmon JE, Askanase A, Bathon JM, Geraldino-Pardilla L, Ali Y, Ginzler EM, Putterman C, Gordon C, Helmick CG, Parton H.

Arthritis Care Res (Hoboken). 2019 Jul;71(7):949-960. doi: 10.1002/acr.23707. Epub 2019 May 23.

PMID:
30044541
9.

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.

Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG; AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Investigators.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):134-141. doi: 10.1002/acr.23584.

PMID:
29669399
10.

Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment.

Wang S, Wu M, Chiriboga L, Zeck B, Belmont HM.

Semin Arthritis Rheum. 2018 Oct;48(2):256-262. doi: 10.1016/j.semarthrit.2018.01.004. Epub 2018 Jan 6.

PMID:
29395256
11.

Clinical Reasoning: A 50-year-old woman with SLE and a tumefactive lesion.

Choi JH, Wallach AI, Rosales D, Margiewicz SE, Belmont HM, Lucchinetti CF, Minen MT.

Neurology. 2017 Sep 19;89(12):e140-e145. doi: 10.1212/WNL.0000000000004386. No abstract available.

PMID:
28923891
12.

The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program.

Izmirly PM, Wan I, Sahl S, Buyon JP, Belmont HM, Salmon JE, Askanase A, Bathon JM, Geraldino-Pardilla L, Ali Y, Ginzler EM, Putterman C, Gordon C, Helmick CG, Parton H.

Arthritis Rheumatol. 2017 Oct;69(10):2006-2017. doi: 10.1002/art.40192. Epub 2017 Sep 10.

13.

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, Gonzalez E, Knight JS, Uthman I, Willis R, Zhang Z, Wahl D, Zuily S, Tektonidou MG; APS ACTION.

Lupus. 2018 Mar;27(3):399-406. doi: 10.1177/0961203317724219. Epub 2017 Aug 1.

PMID:
28764618
14.

Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.

Der E, Ranabothu S, Suryawanshi H, Akat KM, Clancy R, Morozov P, Kustagi M, Czuppa M, Izmirly P, Belmont HM, Wang T, Jordan N, Bornkamp N, Nwaukoni J, Martinez J, Goilav B, Buyon JP, Tuschl T, Putterman C.

JCI Insight. 2017 May 4;2(9). pii: 93009. doi: 10.1172/jci.insight.93009. eCollection 2017 May 4.

15.

Disseminated cytomegalovirus infection complicating active treatment of systemic lupus erythematosus: an emerging problem.

Berman N, Belmont HM.

Lupus. 2017 Apr;26(4):431-434. doi: 10.1177/0961203316671817. Epub 2016 Oct 5.

PMID:
27703052
16.

Systemic Lupus Erythematosus Onset Seven Years After Initiation of Highly Active Antiretroviral Therapy in a Patient With Human Immunodeficiency Virus: Literature Review and Update on Disease Mechanism of This Unusual Presentation.

Modjinou DV, Osman JL, Haberman RH, Izmirly PM, Belmont HM.

J Clin Rheumatol. 2016 Sep;22(6):338-40. doi: 10.1097/RHU.0000000000000426. No abstract available.

PMID:
27556247
17.

3 Tesla MRI detects deterioration in proximal femur microarchitecture and strength in long-term glucocorticoid users compared with controls.

Chang G, Rajapakse CS, Regatte RR, Babb J, Saxena A, Belmont HM, Honig S.

J Magn Reson Imaging. 2015 Dec;42(6):1489-96. doi: 10.1002/jmri.24927. Epub 2015 Jun 12.

18.

Pulmonary metastasis in a patient with simultaneous bladder cancer and relapsing granulomatosis with polyangiitis.

Danckers M, Zhou F, Nimeh D, Belmont HM, Steiger DJ.

Am J Case Rep. 2015 May 14;16:287-91. doi: 10.12659/AJCR.893406.

19.

Rapid aneurysm growth and rupture in systemic lupus erythematosus.

Graffeo CS, Tanweer O, Nieves CF, Belmont HM, Izmirly PM, Becske T, Huang PP.

Surg Neurol Int. 2015 Jan 20;6:9. doi: 10.4103/2152-7806.149617. eCollection 2015.

20.

Treatment of systemic lupus erythematosus - 2013 update.

Belmont HM.

Bull Hosp Jt Dis (2013). 2013;71(3):208-13. Review.

21.
22.

Pseudo-pseudo Meigs' syndrome in a patient with systemic lupus erythematosus.

Dalvi SR, Yildirim R, Santoriello D, Belmont HM.

Lupus. 2012 Nov;21(13):1463-6. doi: 10.1177/0961203312461291. Epub 2012 Sep 14. Review.

PMID:
22983642
23.

International consensus for a definition of disease flare in lupus.

Ruperto N, Hanrahan LM, Alarcón GS, Belmont HM, Brey RL, Brunetta P, Buyon JP, Costner MI, Cronin ME, Dooley MA, Filocamo G, Fiorentino D, Fortin PR, Franks AG Jr, Gilkeson G, Ginzler E, Gordon C, Grossman J, Hahn B, Isenberg DA, Kalunian KC, Petri M, Sammaritano L, Sánchez-Guerrero J, Sontheimer RD, Strand V, Urowitz M, von Feldt JM, Werth VP, Merrill JT; Lupus Foundation of America, Inc. International Flare Consensus Initiative.

Lupus. 2011 Apr;20(5):453-62. doi: 10.1177/0961203310388445. Epub 2010 Dec 10.

PMID:
21148601
24.

Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission.

Lydon EJ, Barisoni L, Belmont HM.

Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S144. No abstract available.

PMID:
19646364
25.

Systemic lupus erythematosus in 6 male cocaine users at Bellevue hospital.

Rivera TL, Belmont HM, Weissmann G.

J Rheumatol. 2009 Dec;36(12):2854-5. doi: 10.3899/jrheum.090271. No abstract available.

PMID:
19966204
26.

Gelatinous transformation of the bone marrow in systemic lupus erythematosus.

Yamamoto M, Belmont HM, Utsunomiya M, Hidaka Y, Kishimoto M.

Lupus. 2009 Oct;18(12):1108-11. doi: 10.1177/0961203309106344.

PMID:
19762388
27.

Three-dimensional electrocardiographically gated variable flip angle FSE imaging for MR angiography of the hands at 3.0 T: initial experience.

Lim RP, Storey P, Atanasova IP, Xu J, Hecht EM, Babb JS, Stoffel DR, Chang H, McGorty K, Chen Q, Rusinek H, Belmont HM, Lee VS.

Radiology. 2009 Sep;252(3):874-81. doi: 10.1148/radiol.2531090290. Epub 2009 Jun 30.

28.

Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis.

Izmirly PM, Barisoni L, Buyon JP, Kim MY, Rivera TL, Schwartzman JS, Weisstuch JM, Liu DT, Bernstein S, Tseng CE, Belmont HM, Esmon CT, Merrill JT, Askanase AD, Thomas DB, Clancy RM.

Rheumatology (Oxford). 2009 May;48(5):513-9. doi: 10.1093/rheumatology/kep034. Epub 2009 Mar 13.

29.

Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.

Askanase AD, Wallace DJ, Weisman MH, Tseng CE, Bernstein L, Belmont HM, Seidman E, Ishimori M, Izmirly PM, Buyon JP.

J Rheumatol. 2009 Jan;36(1):89-95. doi: 10.3899/jrheum.070968.

PMID:
19040311
30.

Current therapies for lupus nephritis in an ethnically heterogeneous cohort.

Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD.

J Rheumatol. 2009 Feb;36(2):298-305. doi: 10.3899/jrheum.080335.

PMID:
19040310
31.

Lupus nephritis: treatment issues.

Belmont HM.

BioDrugs. 1999 Jan;11(1):7-19.

PMID:
18031111
32.

Acute gastrointestinal distress syndrome in patients with systemic lupus erythematosus.

Kishimoto M, Nasir A, Mor A, Belmont HM.

Lupus. 2007;16(2):137-41.

PMID:
17402371
33.

Treatment of ANCA-associated systemic vasculitis.

Belmont HM.

Bull NYU Hosp Jt Dis. 2006;64(1-2):60-6. Review.

34.
35.

Aplastic anemia in systemic lupus erythematosus: a distinct presentation of acquired aplastic anemia?

Tagoe C, Shah A, Yee H, Belmont HM.

J Clin Rheumatol. 2001 Dec;7(6):377-83.

PMID:
17039179
36.

Combined oral contraceptives in women with systemic lupus erythematosus.

Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP; OC-SELENA Trial.

N Engl J Med. 2005 Dec 15;353(24):2550-8.

37.

Avascular necrosis prevention with lipitor in lupus erythematosus.

Belmont HM, Lydon E.

Lupus. 2005;14(10):869-70. No abstract available.

PMID:
16302686
38.

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.

Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, Merrill JT, Sammaritano L, Lockshin M, Alarcón GS, Manzi S, Belmont HM, Askanase AD, Sigler L, Dooley MA, Von Feldt J, McCune WJ, Friedman A, Wachs J, Cronin M, Hearth-Holmes M, Tan M, Licciardi F.

Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953-62.

PMID:
15968009
39.

Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Mor A, Bingham CO 3rd, Barisoni L, Lydon E, Belmont HM.

J Rheumatol. 2005 Apr;32(4):740-3. Erratum in: J Rheumatol. 2014 Nov;41(11):2336. Bingham, Clifton 3rd [corrected to Bingham, Clifton O 3rd].

PMID:
15801034
40.

Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy.

Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J.

Arthritis Rheum. 2001 May;44(5):1203-8.

41.

Web alert.

Belmont HM.

Curr Rheumatol Rep. 2000 Feb;2(1):3. No abstract available.

PMID:
11219398
42.

Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?

Belmont HM.

Curr Rheumatol Rep. 1999 Dec;1(2):87-8. Review. No abstract available.

PMID:
11123020
43.

SLE: mechanisms of vascular injury.

Abramson SB, Belmont HM.

Hosp Pract (1995). 1998 Apr 15;33(4):107-10, 113-4, 119-22 passim. Review.

PMID:
9562836
44.

The role of microvasculopathy in the catastrophic antiphospholipid syndrome: comment on the article by Neuwelt et al.

Golden BD, Belmont HM.

Arthritis Rheum. 1998 Apr;41(4):751-3; author reply 753-4, 739. No abstract available.

PMID:
9550493
45.

Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus.

Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, Rediske J, Skovron ML, Abramson SB.

Arthritis Rheum. 1997 Oct;40(10):1810-6.

PMID:
9336415
46.

Enterococcal arthritis with avascular necrosis in a lupus patient.

Markov G, Dobro J, Shankman S, Belmont HM.

Br J Rheumatol. 1996 Jun;35(6):595-7. Review. No abstract available.

PMID:
8670585
47.

Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium.

Belmont HM, Abramson SB, Lie JT.

Arthritis Rheum. 1996 Jan;39(1):9-22. Review. No abstract available.

PMID:
8546744
48.

Postmenopausal hormone therapy and systemic lupus erythematosus.

Buyon JP, Belmont HM, Kalunian KC.

Ann Intern Med. 1995 Dec 15;123(12):961; author reply 962. No abstract available.

PMID:
7486496
49.

Misoprostol and Prednisone Treatment of Lupus Nephritis.

Belmont HM, Kitsis E, Skovron ML, Buyon J, McCullagh E, Abramson S.

Am J Ther. 1995 Dec;2(12):928-932.

PMID:
11854810
50.

Can women with systemic lupus erythematosus safely use exogenous estrogens?

Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J, Sammaritano L, Yung C, Licciardi F, Belmont HM, Hahn BH.

J Clin Rheumatol. 1995 Aug;1(4):205-12.

PMID:
19077980

Supplemental Content

Loading ...
Support Center